Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 2

Status

Completed 3Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 222Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

Electroacupuncture 1Ashwagandha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Chemotherapy-Related Cognitive Impairment × Clear all
NCT05941598 2023-07-14

Electroacupuncture for Chemotherapy-Related Cognitive Impairment

Beijing University of Chinese Medicine

Phase 2 Unknown
100 enrolled

Chemotherapy-Related Cognitive Impairment

NCT04092647 2023-06-15

Ashwagandha for Cognitive Dysfunction

Sutter Health

Phase 2 Unknown
80 enrolled

Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡